An inhibitor of transforming growth factor beta type i receptor ameliorates muscle atrophy in a mouse model of caveolin 3-deficient muscular dystrophy

Laboratory Investigation

Volumn 92, Issue 8, 2012, Pages 1100-1114

  Ohsawa, Yutaka ^a   Okada, Tadashi ^a   Nishimatsu, Shin Ichiro ^a   Ishizaki, Masatoshi ^b   Suga, Tomohiro ^b   Fujino, Masahiro ^a   Murakami, Tatsufumi ^a   Uchino, Makoto ^b   Tsuchida, Kunihiro ^c   Noji, Sumihare ^d   Hinohara, Atsushi ^e   Shimizu, Toshiyuki ^e   Shimizu, Kiyoshi ^e   Sunada, Yoshihide ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

caveolin 3; limb girdle muscular dystrophy 1C; muscular atrophy; myoblast; satellite cell; small molecule kinase inhibitor; transforming growth factor b type I receptor kinase

Indexed keywords

ACTIVIN; CAVEOLIN 3; KI 26894; MYOSTATIN; PROTEIN P21; PROTEIN SERINE THREONINE KINASE INHIBITOR; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SATELLITE CELL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UPREGULATION; WILD TYPE;

ACTIVIN RECEPTORS, TYPE I; ACTIVINS; ANIMALS; CAVEOLIN 3; CELL DIFFERENTIATION; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; MALE; MICE; MICE, TRANSGENIC; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; MYOBLASTS; MYOSTATIN; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SATELLITE CELLS, SKELETAL MUSCLE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84864464834     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.78     Document Type: Article

References (49)

1. Tsuchida K, Nakatani M, Uezumi A, et al. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J 2008;55:11-21.
2. Tisdale MJ. Reversing cachexia. Cell 2010;142:511-512.
3. Glass DJ. Signaling pathways perturbing muscle mass. Curr Opin Clin Nutr Metab Care 2010;3:225-229.
4. Guglieri M, Bushby K. Molecular treatments in Duchenne muscular dystrophy. Curr Opin Pharmacol 2010;10:331-337.
5. Ohsawa Y, Hagiwara H, Nakatani M, et al. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 2006;116:2924-2934.
6. Ohsawa Y, Okada T, Kuga A, et al. Caveolin-3 regulates myostatin signaling. Mini-review. Acta Myol 2008;27:19-24.
7. Mcpherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997;387: 83-90.
8. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002;296: 1486-1488.
9. Gazzerro E, Sotgia F, Bruno C, et al. Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 2010;18:137-145.
10. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18:365-368.
11. Sunada Y, Ohi H, Hase A, et al. Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet 2001;10:173-178.
12. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004;3: 1011-1022.
13. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129.
14. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998; 67:753-791.
15. Uhl M, Aulwurm S, Wischhusen J, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004;64:7954-7961.
16. Bandyopadhyay A, Agyin JK, Wang L, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006;66:6714-6721.
17. Ehata S, Hanyu A, Fujime M, et al. Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007;98:127-133.
18. Kano MR, Bae Y, Iwata C, et al. Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 2007;104:3460-3465.
19. Callahan JF, Burgess JL, Fornwald JA, et al. Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5). J Med Chem 2002;45:999-1001.
20. Sawyer JS, Anderson BD, Beight DW, et al. Synthesis and activity of new aryl-and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 2003;46:3953-3956.
21. Jonk LJ, Itoh S, Heldin CH, et al. Identification and functional characterization of a Smad binding elements (SBE) in theJunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 1998; 273:21145-21152.
22. Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol 2003;31:1007-1014.
23. Rosenblatt JD, Lunt AI, Parry DJ, et al. Culturing satellite cells from living single muscle fiber explants. In Vitro Cell Dev Biol Anim 1995;31:773-779.
24. Matsuda R, Nishikawa A, Tanaka H. Visualization of dystrophic muscle fibres in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J Biochem 1995;118: 959-964.
25. Xiao X, Li J, Tsao YP, et al. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000;74:1436-1442.
26. Luo Y, Hurwitz J, Massagué J. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature 1995;375:159-161.
27. Ríos R, Carneiro I, Arce VM, et al. Myostatin is an inhibitor of myogenic differentiation. Am J Physiol Cell Physiol 2002;282:C993-C999.
28. Galbiati F, Volonte D, Engelman JA, et al. Targeted down-regulation of caveolin-3 is sufficient to inhibit myotube formation in differentiating C2C12 myoblasts. Transient activation of p38 mitogen-activated protein kinase is required for induction of caveolin-3 expression and subsequent myotube formation. J Biol Chem 1999;274:30315-30321.
29. Stoppani E, Rossi S, Meacci E, et al. Point mutated caveolin-3 form (P104L) impairs myoblast differentiation via Akt and p38 signalling reduction, leading to an immature cell signature. Biochim Biophys Acta 2011;1812:468-479.
30. Vassalli A, Matzuk MM, Gardner HA, et al. Activin/inhibin beta B subunit gene disruption leads to defects in eyelid development and female reproduction. Genes Dev 1994;15:414-427.
31. Cerletti M, Shadrach JL, Jurga S, et al. Regulation and function of skeletal muscle stem cells. Cold Spring Harb Symp Quant Biol 2008; 73:317-322.
32. Volonte D, Liu Y, Galbiati F. The modulation of caveolin-1 expression controls satellite cell activation during muscle repair. FASEB J 2005; 19:237-239.
33. Fabian MA, Biggs 3rd WH, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23:329-336.
34. Olson EN, Sternberg E, Hu JS, et al. Regulation of myogenic differentiation by type beta transforming growth factor. J Cell Biol 1986;103:1799-1805.
35. Massagué J, Cheifetz S, Endo T, et al. Type beta transforming growth factor is an inhibitor of myogenic differentiation. Proc Natl Acad Sci USA 1986;83:8206-8210.
36. Shiozuka M, Kimura I. Developmental stage-related sensitivity of chick primary myogenic cells to differentiation-inhibiting effect of activin A. J Hum Sci 1999;11:56-63.
37. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE 2007;2:E789.
38. Lee SJ, Lee YS, Zimmers TA, et al. Regulation of muscle mass by follistatin and activins. Mol Endocrinol 2010;24:1998-2008.
39. Bernasconi P, Torchiana E, Confalonieri P, et al. Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995;96:1137-1144.
40. Cohn RD, van Erp C, Habashi JP, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007;13:204-210.
41. Carlson ME, Hsu M, Conboy IM. Imbalance between pSmad3 and notch induces CDK inhibitors in old muscle stem cells. Nature 2008;454:528-532.
42. Mccroskery S, Thomas M, Maxwell L, et al. Myostatin negatively regulates satellite cell activation and self-renewal. J Cell Biol 2003;162: 1135-1147.
43. Amthor H, Otto A, Vulin A, et al. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci USA 2009;106:7479-7484.
44. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008;63: 561-571.
45. Amthor H, Macharia R, Navarrete R, et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA 2007;104:1835-1840.
46. Yokota T, Lu QL, Partridge T, et al. Efficacy of systemic morpholino exonskipping in Duchenne dystrophy dogs. Ann Neurol 2009;65:667-676.
47. Bonniaud P, Margetts PJ, Kolb M, et al. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005;171:889-898.
48. Moon JA, Kim HT, Cho IS, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006;70:1234-1243.
49. Hayashi YK, Matsuda C, Ogawa M, et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest 2009;119:2623-2633.